Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 19;213(10):1999–2018. doi: 10.1084/jem.20160393

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Bajrami et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 5. — G-CSF inhibits MIP-2–induced neutrophil chemotaxis. (A) Chemotaxis of untreated or G-CSF–treated mouse neutrophils (also see Videos 5, 6, and 7). (B) Tracks of migrating neutrophils (cells that moved at least 65 µm from the bottom of the channel; n = 10) were traced from the captured images, realigned such that all cells started from the same starting point (0,0), and plotted. Chemoattractant concentration increases in the positive y direction. (C–E) Tracks of migrating neutrophils were analyzed to determine directionality, upward directionality, and migration speed. (F) G-CSF does not affect chemotaxis elicited by LTB4, C5a, and fMLP in mouse neutrophils (also see Videos 8 and 9). (G) G-CSF specifically suppresses MIP-2–mediated chemotaxis of human neutrophils. Data are represented as means ± SD of three experiments (n = 20 cells). *, P < 0.01 versus neutrophils not treated with G-CSF.